Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of AIBP in treating or inhibiting hemangioma

A hemangioma and overexpression technology, applied in the field of biomedicine, can solve problems such as lack of research, and achieve highly applicable effects

Pending Publication Date: 2021-07-27
NANTONG UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of AIBP in hemangiomas has not been studied so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of AIBP in treating or inhibiting hemangioma
  • Application of AIBP in treating or inhibiting hemangioma
  • Application of AIBP in treating or inhibiting hemangioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment one, experimental material

[0024] 1. Matrigel was purchased from BD bioscience;

[0025] 2. rhAIBP was purchased from Beijing Yiqiao Shenzhou Company;

[0026] 3. Heparin was purchased from Sigma;

[0027] 4. DMEM was purchased from HyClone;

[0028] 5. F12K was purchased from Sciencell;

[0029] 6. Phosphate Buffered Saline (1×) was purchased from HyClone Company;

[0030] 7. Penicillin-Streptomycin Solution was purchased from HyClone Company;

[0031] 8. Fetal bovine serum was purchased from Sijiqing Company.

Embodiment 2

[0032] Embodiment two, experimental method

[0033] 1. Tube formation (tube formation experiment)

[0034] (1) Seed human hemangioma endothelial cells (HemECs) into six-well plates, 3×10 5 / Each well was cultured with DMEM / F12K medium, and after the cells adhered to the wall, they were starved overnight with serum-free basal medium.

[0035] (2) After the starvation was completed, the cell medium was changed, and the serum-free medium was replaced with DMEM / F12K medium, and the experimental group was treated with human recombinant protein AIBP (rhAIBP) for 24 hours.

[0036] (3) Take the melted matrigel, spread 50ul per well into a 96-well plate, place it in a 37-degree incubator and incubate for 30 minutes until it solidifies.

[0037] (4) Aspirate the cell solution in the 6-well plate, wash it with PBS, add trypsin to digest for 3 minutes, and stop the digestion. After centrifugation, use fresh DMEM / F12K to complete the culture to resuspend the cells, and use a hemocytome...

Embodiment 3

[0049] Example 3. Recombinant protein AIBP inhibits tube formation and migration of human hemangioma endothelial cells

[0050] As a secreted protein, AIBP can inhibit retinal angiogenesis in zebrafish and mice. Hemangioma is a common tumor in infants, and its pathophysiological mechanism is to form new blood vessels. Therefore, the present invention proposes that AIBP may also play an important role in the occurrence of hemangioma .

[0051] In order to confirm this hypothesis, the present invention first uses recombinant human AIBP protein to conduct tube formation experiments in human hemangioma endothelial cells. The results of tube-forming experiments showed that compared with the control group (CTR), the tube-forming ability of hemangioendothelial cells HemECs in the secretory protein AIBP treatment group (AIBP+) was significantly weakened, as shown in figure 1 As shown in A. At the same time, the present invention detects whether AIBP affects the migration ability o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of overexpressed AIBP in the aspect of treating or inhibiting hemangioma. The invention discloses application of overexpressed AIBP in preparation of drugs for treating or inhibiting hemangioma. A drug for treating or inhibiting hemangioma is characterized in that the drug at least contains recombinant human AIBP protein. The invention further discloses a method for verifying the efficacy of the drug for treating or inhibiting hemangioma prepared from AIBP, which comprises the following steps: (1) recombining human AIBP protein, and carrying out an experiment in human hemangioma endothelial cells to verify the migration ability of AIBP in inhibiting HemECs; (2) constructing an AIBP overexpression plasmid, and then establishing an AIBP stable overexpression HemECs cell; (3) after the AIBP is stably knocked out from the HemECs, verifying the healing ability after damage; and (4) verifying the tumor formation capability of the HemECs cells with stable overexpression of the AIBP in vivo. According to the invention, a new target spot for treating or inhibiting hemangioma is found, and a new treatment method or treatment drug possibility is provided for hemangioma patients.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of AIBP in treating or inhibiting hemangioma. Background technique [0002] Hemangioma is a benign tumor derived from blood vessels. It often occurs in infants and young children. It can appear in various tissues and organs of the body, including internal organs. It is often found on the skin of the face, scalp, chest and back. A hemangioma that occurs in the skin is bright red, with excess blood vessels protruding from the skin as a spongy or rubbery bump. Most infantile hemangiomas will subside naturally by the age of 5 and up to 10 years old. Therefore, in general, they are not treated. However, if the hemangioma interferes with breathing, vision and other functions or has symptoms such as ulceration and bleeding, then treatment is required. [0003] Clinically, hemangioma has the pathological characteristics of proliferative phase and regressi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A01K67/027C12Q1/02C12N15/85C12N15/55C12N15/12C12N5/10A61P35/00
CPCA61K38/1709A61P35/00G01N33/5011C12N15/85C12N9/22C07K14/47C12N5/0693C12N5/069A01K67/0278C12N2503/02G01N2500/10C12N2800/107C12N2510/00A01K2227/105A01K2267/035
Inventor 毛仁芳
Owner NANTONG UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com